These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

658 related items for PubMed ID: 26145447

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Ceftazidime-avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.
    Mawal Y, Critchley IA, Riccobene TA, Talley AK.
    Expert Rev Clin Pharmacol; 2015; 8(6):691-707. PubMed ID: 26420166
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Ceftazidime/avibactam: a novel cephalosporin/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.
    Hidalgo JA, Vinluan CM, Antony N.
    Drug Des Devel Ther; 2016; 10():2379-86. PubMed ID: 27528799
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Ceftazidime-avibactam: novel antimicrobial combination for the treatment of complicated urinary tract infections.
    Alidjanov JF, Fritzenwanker M, Hoffman I, Wagenlehner FM.
    Future Microbiol; 2017 Jun; 12():655-670. PubMed ID: 28338347
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
    Liscio JL, Mahoney MV, Hirsch EB.
    Int J Antimicrob Agents; 2015 Sep; 46(3):266-71. PubMed ID: 26143591
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. In Vitro Activity of Ceftazidime-Avibactam against Isolates in a Phase 3 Open-Label Clinical Trial for Complicated Intra-Abdominal and Urinary Tract Infections Caused by Ceftazidime-Nonsusceptible Gram-Negative Pathogens.
    Stone GG, Bradford PA, Newell P, Wardman A.
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872067
    [Abstract] [Full Text] [Related]

  • 14. Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections.
    Shirley M.
    Drugs; 2018 Apr; 78(6):675-692. PubMed ID: 29671219
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. In vitro activity of ceftazidime/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infections.
    Stone GG, Bradford PA, Yates K, Newell P.
    J Antimicrob Chemother; 2017 May 01; 72(5):1396-1399. PubMed ID: 28088768
    [Abstract] [Full Text] [Related]

  • 17. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.
    Zhanel GG, Lawson CD, Adam H, Schweizer F, Zelenitsky S, Lagacé-Wiens PR, Denisuik A, Rubinstein E, Gin AS, Hoban DJ, Lynch JP, Karlowsky JA.
    Drugs; 2013 Feb 01; 73(2):159-77. PubMed ID: 23371303
    [Abstract] [Full Text] [Related]

  • 18. Population Pharmacokinetic Modeling and Probability of Pharmacodynamic Target Attainment for Ceftazidime-Avibactam in Pediatric Patients Aged 3 Months and Older.
    Franzese RC, McFadyen L, Watson KJ, Riccobene T, Carrothers TJ, Vourvahis M, Chan PLS, Raber S, Bradley JS, Lovern M.
    Clin Pharmacol Ther; 2022 Mar 01; 111(3):635-645. PubMed ID: 34687548
    [Abstract] [Full Text] [Related]

  • 19. Ceftazidime-Avibactam Activity against Aerobic Gram Negative Organisms Isolated from Intra-Abdominal Infections in United States Hospitals, 2012-2014.
    Sader HS, Castanheira M, Flamm RK, Huband MD, Jones RN.
    Surg Infect (Larchmt); 2016 Aug 01; 17(4):473-8. PubMed ID: 27104633
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.